Literature DB >> 7207617

Normal levels of natural cytotoxic cells against solid tumours in NK-deficient beige mice.

O Stutman, M J Cuttito.   

Abstract

Natural cell-mediated cytotoxicity (NCMC) capable of in vitro lysis of various lymphoid and non-lymphoid tumours has been described in mice and other species, including man. NCMC has been proposed as a first level of defence against tumour growth in vivo, one which does not need the priming of the conventional immunological response. The effector cells of NCMC seem to belong to a special category of lymphoid cells, being neither classical T or B cells nor macrophages; natural killer (NK) cells have been proposed as the prototype effector cell, although some heterogeneity among effector cells seems to exist, depending on the target cells used for testing. Two main subgroups of NCMC effector cells have been defined: NK cells directed against lymphoma targets and natural cytotoxic (NC) cells directed against solid non-lymphoid tumours. We describe here another distinction between the two systems: while NK activity is low in mice homozygous for the beige (bg) gene NC activity in spleen cell preparations from these animals is comparable with that observed in the appropriate controls (bg/+ and +/+ littermates). The bg syndrome of mice affects lysosome, melanosome and enzymatic functions and is a homologue of the Chediak--Higashi syndrome of man. Defective NK activity in blood lymphocytes has also been reported in patients with Chediak--Higashi syndrome. We also show that several mouse strains which have low NK activity, have normal or high levels of NC functions, expanding our previous observation that NC and NK cells are under distinct genetic control.

Entities:  

Mesh:

Year:  1981        PMID: 7207617     DOI: 10.1038/290254a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  16 in total

1.  The Nul subunit of bacteriophage lambda terminase binds to specific sites in cos DNA.

Authors:  G Shinder; M Gold
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

2.  Reduced natural cytotoxic cell activity in patients receiving cisplatin-based chemotherapy and in mice treated with cisplatin.

Authors:  C B Powell; D G Mutch; M S Kao; J L Collins
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

Review 3.  Natural killer activity: early days, advances, and seminal observations.

Authors:  John R Ortaldo; Robert H Wiltrout; Craig W Reynolds
Journal:  Crit Rev Oncog       Date:  2014

4.  The anticancer drug, cisplatin, increases the naturally occurring cell-mediated lysis of tumor cells.

Authors:  J L Collins; M S Kao
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Natural cytotoxic (NC) activity: a multi-lineage system regulated by IL-2.

Authors:  E C Lattime; M J Bykowsky; O Stutman
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

6.  Deficient natural killer cell activity in alcoholic cirrhosis.

Authors:  B Charpentier; D Franco; L Paci; M Charra; B Martin; D Vuitton; D Fries
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

7.  Natural cytotoxicity in lymphatic metastasis. II. In vivo studies with BSp73 variants differing in metastatic capacity.

Authors:  S Matzku
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

8.  Human neuroblastoma cell growth in xenogeneic hosts: comparison of T cell-deficient and NK-deficient hosts, and subcutaneous or intravenous injection routes.

Authors:  W J Turner; J Chatten; L A Lampson
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

9.  Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

Authors:  G Schulz; T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

10.  Enhanced resistance to acute infection with Trypanosoma cruzi in mice treated with an interferon inducer.

Authors:  S L James; T L Kipnis; A Sher; R Hoff
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.